If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
53
results.
Updated on
15/07/2026 [06:45:00]
Results 25 to 50 of 53
Absstract of: EP4768029A2
0001 Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced squamous cell carcinoma of the head and neck, colorectal cancer, non-small cell lung cancer, and transitional cell carcinoma of the bladder. Also provided herein are methods of treating blood cancers, such as acute myeloid leukemia, in a subject in need thereof.
Absstract of: MA69025A1
The present invention describes an intelligent, integrated device for the automated and accurate diagnosis of leukaemia. This system combines advanced technologies, including automated blood smear preparation, infrared spectroscopy and microscopic imaging, with artificial intelligence (AI) algorithms. It enables real-time analysis of blood biomarkers and microscopic images, while ensuring standardised, high-quality sample preparation. The architecture of the device is designed to optimise the flow of data, from the initial acquisition of samples to the generation of final diagnoses. The device is structured around the following main components: - Intelligent Sample Preparation and Processing Unit (1) - Integrated Microscopic Acquisition Module (2) - Infrared Spectral Analysis Module (3) - Waste Management Box (4) - Embedded Processing Unit (5) - Cloud Infrastructure (6) - Graphical Interface (7)
Absstract of: KR20260101631A
0001a 본 발병은 미토콘드리아 호흡 복합체Ⅰ(NADH:유비퀴논 산화환원효소) 저해제를 유효성분으로 포함하는 급성 골수성 백혈병 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 미토콘드리아 호흡 복합체Ⅰ 저해제를 포함하는 조성물은 불응 또는 재발성 급성 골수성 백혈병 세포 생존율을 현저하게 감소시키는 효과가 있는바, 급성 골수성 백혈병 치료제로 유용하게 사용될 수 있다.
Absstract of: WO2026136325A2
Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and/or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.
Absstract of: WO2026132502A2
Methods of predicting whether a subject with chronic myelogenous leukaemia (CML) is at risk of relapse following cessation of a treatment for CML, whether a subject with CML will achieve TFR following cessation of a treatment for CML, and selecting a subject for treatment, wherein the subject has CML or has been diagnosed with CML are disclosed herein. The methods comprise determining the expression of one or more genes regulated by PRC1. Also provided are kits and antigen-binding molecules suitable for use in the disclosed methods.
Absstract of: US20260176325A1
0000 Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
Absstract of: WO2026129324A1
A preparation method for and a use of a chimeric antigen receptor (CAR)-γδT cell for immunotherapy of T cell acute lymphoblastic leukemia, relating to the field of biomedicine. The provided anti-CD5 nanobody can specifically bind to a CD5 antigen, and has good affinity. By using the anti-CD5 nanobody as an antigen-binding domain to construct a CAR, the prepared CAR-γδT cell exhibits significant killing activity against CD5-positive tumor cell lines, such as T cell acute lymphoblastic leukemia cells.
Absstract of: US20260174766A1
0000 In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the invention is related to a pharmaceutical preparation comprising at least one menin inhibitor and at least one immunoproteasome inhibitor, optionally one or more pharmaceutically acceptable carrier(s) and optionally one or more pharmaceutically acceptable adjuvant(s).
Absstract of: US20260174866A1
0000 Methods of treating non-Hodgkin lymphoma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.
Absstract of: WO2026130838A1
(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.
Absstract of: WO2026136291A1
In one aspect, the disclosure relates to compounds that behave as molecular glue degraders (MGDs) and methods of making and using same. In various aspects, the disclosed compounds are useful for modulating PPIL4 activity through targeted degradation. In various aspects, the compounds are useful for treating medulloblastoma and/or acute lymphoblastic leukemia (ALL). In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using the same, such as T-cell acute lymphoblastic leukemia. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: US20260176692A1
0000 Certain embodiments of the invention provide a method of preventing or treating a B cell mediated disorder, such as B cell lymphoma and/or lupus.
Absstract of: US20260176335A1
0000 The present disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.
Absstract of: WO2026132392A1
The present invention is directed to SEL24/MEN1703 for use in the treatment of a patient suffering from cancer and/or for use in increasing the overall survival of a patient suffering from cancer, wherein the cancer is myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and wherein said patient carries at least one mutation in at least one gene associated with splicing.
Absstract of: US20260176355A1
0000 The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Absstract of: EP4763863A1
Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Absstract of: ES3071686A2
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Absstract of: EP4763279A2
This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).
Absstract of: WO2020117257A1
Provided herein are methods of treating B-cell proliferative disorders (such as Diffuse Large B-Cell Lymphoma "DLBCL") using immunoconjugates comprising anti-CD79b antibodies in combination with an alkylating agent (such as bendamustine) and an anti-CD20 antibody (such as rituximab).
Absstract of: AU2024370696A1
Methods are provided for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from <5% to >10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody.
Absstract of: WO2026128374A1
Engineered extracellular vesicle having a first fusion protein comprising an anti-CD3 antibody moiety, an anti-CLL-1 antibody moiety, and a first transmembrane domain, a second 5 fusion protein comprising a PD-1 protein, a second transmembrane domain, and a CD70 protein, such that both the first fusion protein and the second fusion protein are displayed on a surface of the engineered extracellular vesicle, and methods of using the same.
Absstract of: US20260167647A1
This disclosure provides chemical entities (e.g., a compound, or a pharmaceutically acceptable salt thereof, or an atropisomer thereof; or a pharmaceutically acceptable salt of an atropisomer) that modulate (e.g., inhibit) the interaction between menin and mixed-lineage leukaemia (“MLL”) proteins (e.g., MLL fusion proteins). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a condition, disease or disorder in which aberrant (e.g., increased, e.g., excessive) menin-MLL interaction contribute to the pathology, symptoms and/or progression of the condition, disease or disorder (e.g., cancer, diabetes). This disclosure also provides compositions containing the chemical entities as well as methods of making and using the same . . . .
Absstract of: US20260166038A1
A method of enhancing the efficacy of a targeted protein degrader and its derivative therapeutics is provided. The mTOR inhibitor can significantly enhance the degradation of substrates by targeted protein degraders such as molecular glue degraders and PROTACs, thereby achieving therapeutic purposes. Moreover, the combination therapy is particularly suitable for myeloma patients who have developed resistance to immunomodulatory drugs (IMiDs), a kind of molecular glue degrader, of which the continuous use resulting in reduced treatment efficacy and myeloma relapse. Also provided is a pharmaceutical composition, which comprises a targeted protein degrader and its derivative therapeutics, and a mTOR inhibitor. By promoting the degradation of substrates by targeted protein degrader and its derivative therapeutics, the effectiveness of such drugs in treating disease can be increased.
Absstract of: AU2024370574A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.
Nº publicación: US20260166082A1 18/06/2026
Applicant:
CELGENE CORP [US]
Celgene Corporation
Absstract of: US20260166082A1
Provided herein are adoptive cell therapy methods involving the administration of genetically engineered cells followed by an immunomodulatory agent maintenance therapy for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM), such as high risk multiple myeloma or newly diagnosed multiple myeloma (NDMM). In some embodiments, the methods are for treating subjects who experienced an early relapse, an inadequate response or a suboptimal response after frontline autologous stem cell transplant therapy (ASCT).
BOPI
Electronic site
